PN20

DRUG3 trials

Sponsors

Chongqing Peg-Bio Biopharm Co., Ltd.

Conditions

Chemotherapy-induced ThrombocytopeniaImmune Thrombocytopenic PurpuraThrombocytopeniaThrombocytopenia Associated With Chronic Liver Disease

Phase 1

A Study of PN20 in Healthy Adult Volunteers

CompletedNCT06523088

Chongqing Peg-Bio Biopharm Co., Ltd.Chemotherapy-induced Thrombocytopenia, Immune Thrombocytopenic Purpura

Start: 2022-06-16End: 2023-01-05Updated: 2025-03-13

A Study of PN20 for the Prevention of Chemotherapy-induced Thrombocytopenia in Lymphoma or Solid Tumor Patients

CompletedNCT06521931

Chongqing Peg-Bio Biopharm Co., Ltd.Thrombocytopenia

Start: 2023-12-06End: 2025-01-13Updated: 2026-03-02

A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure

RecruitingNCT07446491

Chongqing Peg-Bio Biopharm Co., Ltd.Thrombocytopenia Associated With Chronic Liver Disease

Start: 2025-06-06End: 2026-06-28Target: 54Updated: 2026-03-03

Related Papers

Efficacy and Safety of Pegylated Peptide Agonist of Thrombopoietin Receptor (PN20) in Secondary Prevention of Chemotherapy-Induced Thrombocytopenias: A Multicenter, Single Arm, Phase Ib Trial

Blood2024-11-05